LegalcommunityMENA’s Post

Meysan has successfully advised Sanam Innovation Holding Company (Sanam Real Estate Company) and Arzan Financial Group For Financing & Investment K.P.S.C. Group on their $33 million acquisition of 75% of National Medical Consumables Industries - NATMED.   The Meysan team, led by Partner Dr. Abdulwahab Sadeq and supported by senior associate Adel Al Asousi and associate Nour Berbari. Read more: https://lnkd.in/d7s56KcX #Meysan #LegalAdvisors #LandmarkDeal #StrategicInvestment

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline https://lnkd.in/dSp5hqXn #pharmaindustry #pharmanews #funding Adcendo TCGX TPG OrbiMed Venrock Surveyor Capital RA Capital Management Novo Holdings Pontifax Venture Capital Dawn Biopharma KKR HealthCap Gilde Healthcare Ysios Capital Michael Pehl Cariad Chester John Haurum Nandita Shangari Jeroen Bakker Carolyn Ng ohad hammer Iyona Rajkomar, MBBS, CFA Roy Amariglio

Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved ·      Funds deposited for cash quota and to cover legal costs ·      European Investment Bank (EIB) agrees to standstill declaration ·      Implementation of the restructuring plan and the Company's sustainable continued existence are to be secured by the sale of the Carragelose business “We have experienced very challenging months. Despite the difficulties, we have been able to develop a restructuring plan that provides an acceptable solution for our creditors and ensures the stable financing of the Company. The two capital increases that have been carried out are also significant for securing our cash situation. We are grateful for the continued support and trust placed in us,” says Andreas Grassauer, CEO of Marinomed. The full press release is available here: https://lnkd.in/dWdc5Qux #oceanofideas

Ord Minnett is pleased to be acting as Joint Lead Manager to Vitrafy Life Sciences Limited (ASX:VFY) on its ~$35.0 million initial public offering (IPO) which commenced trading on the ASX today. Proceeds from the IPO will be used to support Vitrafy’s growth strategies, including by investing in revenue-generation initiatives, market awareness and commercialisation efforts, technology development and general working capital. Vitrafy is an Australian company with the mission to become a global leader in cryopreservation by significantly improving the cell survival of cryopreserved biological materials. Vitrafy has designed and developed an innovative solution for the advancement of cryopreservation, which includes smart devices, a sample quality management software platform, and smart packaging solutions. Vitrafy’s Cryopreservation Technology has been proven to substantially increase cell survival and functionality when compared to many industry and regulatory standards via internal testing and third-party validation studies. Ord Minnett is pleased to support Vitrafy in its initial public offering. We congratulate Vitrafy’s Managing Director and CEO, Kate Munnings, Co-Founder, Executive Director and Deputy CEO, Brent Owens, and the entire Vitrafy team on a successful transaction and look forward to continuing our support of Vitrafy. #ASX #cryopreservation #healthcare #equitycapitalmarkets #IPO #OrdMinnett

Congratulations to the ℝ𝕖𝕒𝕝 𝔻𝕖𝕒𝕝𝕤 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗘𝗾𝘂𝗶𝘁𝘆 𝗔𝘄𝗮𝗿𝗱𝘀 𝟮𝟬𝟮𝟰 𝘿𝙚𝙖𝙡 𝘼𝙬𝙖𝙧𝙙𝙨 𝙒𝙞𝙣𝙣𝙚𝙧𝙨 🏆 Central and Eastern European Deal of the Year: Enterprise Investors for Unilink 🏆 DACH Deal of the Year: Oakley Capital for IU Group 🏆 France and Benelux Deal of the Year: ARCHIMED for Polyplus 🏆 Mediterranean Deal of the Year: Wise Equity for Cantiere del Pardo S.p.A. 🏆 Nordic Deal of the Year: Norvestor for Kabal 🏆 UK Small-Cap Deal of the Year (EV on entry less than €25m): AURELIUS for Distrelec 🏆 UK Lower Mid-Cap Deal of the Year (EV on entry of €25-100m): Palatine for Anthesis Group 🏆 UK Upper Mid-Cap Deal of the Year (EV on entry of €100m+): Equistone Partners Europe for Acuity Knowledge Partners

Sidetrade discussed in detail the highly promising acquisition of SHS Viveon. This deal once again confirms Sidetrade's ability to seize M&A opportunities likely to boost its organic growth potential at prices far removed from market standards. #SidetradeALeader

Another week, another round of hot deals and exciting news in the world of M&A! We've handpicked a selection of last week's closed deals for you. For more details and to discover all the deals in the sector that interests you (and much more!): https://lnkd.in/enTvMFuU News Week 13-24 🚀 Add-on MoxeXM (Hesse / DEU), a specialist in software and platform development for customer experience management (CXM), acquires Feeddex and 5-sterrenspecialist. This double acquisition, supported by Pride Capital Partners, enables MoxeXM to expand its CXM offering in Europe. 🚀 Acquisition Accession Capital Partners invests in WAWRZASZEK ISS (WISS) (Silesia / POL), a manufacturer of specialized fire and emergency vehicles. ACP will support the company's growth in partnership with founder Piotr Wawrzaszek and his family. 🚀 Acquisition Siparex acquires a majority stake in Capron Podologie (c. €23M in revenue in 2023, Bourgogne-Franche-Comté / FRA), a manufacturer of equipment for podiatrists and chiropodists. This transaction, led by the Siparex Midcap 4 fund, will enable the company to accelerate its international expansion. 🚀 Exit Ingersoll Rand ($5.5 billion of revenue in 2022, Leinster / IRL), an industrial company specializing in the design and manufacture of compressors, blowers, pumps, vacuum products, fluid transfer products, and material handling equipment, has acquired ILC Dover (Delaware / USA), a company specializing in the design and production of flexible containment solutions for the biopharmaceutical, pharmaceutical, medical device, and aerospace markets. With this acquisition, Ingersoll will expand its customer base and develop in high-growth end markets such as life sciences. Notably, ILC Dover's investors included Linden Capital Partners and New Mountain Capital, who thus contributed to its success. Don't miss the latest trends and news from the world of investment funds by following our page. #InvestmentFunds #PrivateEquity #MergerandAcquisition

Thrilled by Eurazeo’s H1 successes we had the pleasure to present with William Kadouch-Chassaing.   Our H1 results reflected the successful execution of our strategic plan in line with our medium-term objectives presented to the market in November 2023. We reported a dynamic growth in asset management with a strong momentum in fundraising up +63% with €2.1bn raised in H1 2024, including €453M from private clients. We also increased realizations, including Amolyt Pharma (Biotech), Onfido (Venture), LumApps (Growth), EFESO Management Consultants, DORC Dutch Ophthalmic Research Center (International), Peters Surgical, and I-TRACING.   We warmly thank our more than 400 great talents, as well as our clients, investors, entrepreneurs and shareholders for their trust and support in the implementation of our strategic roadmap.   🔎 Read more: https://lnkd.in/eY89RySe   #PrivateEquity #AssetManagement #MidMarket #Growth #Impact #strategy #PowerBetterGrowth #results #finance

👏 Former SETsquared Scale-Up Programme member, iFAST Diagnostics, has announced the closure of its successful $6.5m (£5m) seed round, allowing them to bring their rapid antimicrobial susceptibility testing (AST) test to the UK market as soon as early 2025. While traditional AST methods require 48 to 72 hours, the iFAST system reduces this testing time to under three hours - delivering the potential to improve patient outcomes whilst making sure that patients receive the right treatment at the right time. To support this mission, iFAST has seen significant investment through its recent oversubscribed round, led by KHP Ventures, the first NHS-anchored venture fund, alongside existing investors QantX, UKI2S (Managed by Future Planet Capital, Kadmos, and several angel investors. New investors, EInk, Raw Ventures, and OKG Capital also contributed to the round. Get the full story 👉 https://lnkd.in/gDYNxZvf #MedTech #Medicine #AMR #AntibioticResistance